Abstract
The challenges in preventing and controlling tuberculosis are further complicated by the deadly rise of multidrug- resistant tuberculosis (MDR-TB). Recognizing the seriousness of the situation, we initiated a program to screen new agents that would satisfy these unmet needs and have a favorable safety profile. Mycobacteria are well known for their lipid-rich properties. In Mycobacterium tuberculosis, mycolic acid in particular has been established the wall component related to the pathogenesis in the host. There are approximately 250 identified genes related to biosynthesis of the lipid turnover that contain InhA, the main target of isoniazid. Thus, the logical approach for developing a chemotherapy agent against tubercle bacilli included screening compounds that could inhibit the biosyntheses of mycolic acid and that had a novel chemical structure to ensure improved efficacy against MDR-TB. Some of the screening systems established for those purposes and some of the candidates are outlined.
Keywords: Tuberculosis, mycolic acid inhibitor, nitrodehydroimidazooxazole, mycolic acid, BRM test
Current Topics in Medicinal Chemistry
Title: Screening for Novel Antituberculosis Agents that are Effective Against Multidrug Resistant Tuberculosis
Volume: 7 Issue: 5
Author(s): Makoto Matsumoto, Hiroyuki Hashizume, Hidetsugu Tsubouchi, Hirofumi Sasaki, Motohiro Itotani, Hideaki Kuroda, Tatsuo Tomishige, Masanori Kawasaki and Makoto Komatsu
Affiliation:
Keywords: Tuberculosis, mycolic acid inhibitor, nitrodehydroimidazooxazole, mycolic acid, BRM test
Abstract: The challenges in preventing and controlling tuberculosis are further complicated by the deadly rise of multidrug- resistant tuberculosis (MDR-TB). Recognizing the seriousness of the situation, we initiated a program to screen new agents that would satisfy these unmet needs and have a favorable safety profile. Mycobacteria are well known for their lipid-rich properties. In Mycobacterium tuberculosis, mycolic acid in particular has been established the wall component related to the pathogenesis in the host. There are approximately 250 identified genes related to biosynthesis of the lipid turnover that contain InhA, the main target of isoniazid. Thus, the logical approach for developing a chemotherapy agent against tubercle bacilli included screening compounds that could inhibit the biosyntheses of mycolic acid and that had a novel chemical structure to ensure improved efficacy against MDR-TB. Some of the screening systems established for those purposes and some of the candidates are outlined.
Export Options
About this article
Cite this article as:
Matsumoto Makoto, Hashizume Hiroyuki, Tsubouchi Hidetsugu, Sasaki Hirofumi, Itotani Motohiro, Kuroda Hideaki, Tomishige Tatsuo, Kawasaki Masanori and Komatsu Makoto, Screening for Novel Antituberculosis Agents that are Effective Against Multidrug Resistant Tuberculosis, Current Topics in Medicinal Chemistry 2007; 7 (5) . https://dx.doi.org/10.2174/156802607780059727
DOI https://dx.doi.org/10.2174/156802607780059727 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advancement in Vaccinology: New Era in Formulation Strategies
Current Drug Therapy Advances in the Synthesis of Calystegines and Related Products and their Biochemical Properties
Mini-Reviews in Medicinal Chemistry Recurrent Episodes of Pericardial Effusion as Isolated Manifestation of Tuberculosis: Case Report
Current Medical Imaging Exploring and Exploiting Biologically Relevant Chemical Space
Current Drug Targets Radiolabelled Peptides: Eon in Radiopharmaceutical
Current Radiopharmaceuticals Cyclodextrin Inclusion Complexes Loaded in Particles as Drug Carrier Systems
Current Topics in Medicinal Chemistry Pulmonary Drug Delivery System: A Novel Approach for Drug Delivery
Current Drug Therapy A High Fundamental Frequency (HFF)-based QCM Immunosensor for Tuberculosis Detection
Current Topics in Medicinal Chemistry Novel Applications of Nanotechnology in Controlling HIV and HSV Infections
Current Drug Research Reviews Current Therapeutic Options for the Treatment of Juvenile Idiopathic Arthritis
Current Rheumatology Reviews Impairment of T Cell Immunity by the Respiratory Syncytial Virus: Targeting Virulence Mechanisms for Therapy and Prophylaxis
Current Medicinal Chemistry Angiogenin as a Molecular Target for the Treatment of Prostate Cancer
Current Cancer Therapy Reviews QSAR, Docking, and CoMFA Studies of GSK3 Inhibitors
Current Pharmaceutical Design Modulation of Cytokine Network in the Comorbidity of Schizophrenia and Tuberculosis
Current Topics in Medicinal Chemistry Synthesis and Antimicrobial Activities of Hybrid Heterocyclic Molecules Based on 1-(4-Fluorophenyl)piperazine Skeleton
Letters in Drug Design & Discovery Computational Sampling and Simulation Based Assessment of Novel <i>Mycobacterium tuberculosis</i> Glutamine Synthetase Inhibitors: Study Involving Structure Based Drug Design and Free Energy Perturbation
Current Topics in Medicinal Chemistry Recombinant Murine Polyoma Virus-like-particles Induce Protective Antitumour Immunity
Letters in Drug Design & Discovery Appreciating the Balance between Classical Interleukin (IL)-6 Receptor Signaling and IL-6 Trans-Signaling: Implications for Arthritis Progression
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Allergic Aspergillosis and the Antigens of Aspergillus fumigatus
Current Protein & Peptide Science Plombage: A Forgotten Surgical Treatment for Pulmonary Tuberculosis
Current Respiratory Medicine Reviews